Masuda, Norikazu
Inoue, Kenichi
Nakamura, Rikiya
Rai, Yoshiaki
Mukai, Hirofumi
Ohno, Shinji
Hara, Fumikata
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Huang, Xin
Iwata, Hiroji
Funding for this research was provided by:
Pfizer
Article History
Received: 20 June 2018
Accepted: 12 October 2018
First Online: 3 November 2018
Compliance with ethical standards
:
: N. Masuda has received honoraria from Chugai, AstraZeneca, Pfizer, and Takeda; and research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, and Daiichi Sankyo; H. Iwata has received honoraria and research funding from Pfizer and AstraZeneca, and fees for promotional materials from AstraZeneca; F. Hara, H. Mukai, R. Nakamura, and Y. Rai have no conflicts of interest to report; K. Inoue has received research funding from Parexel, Puma Biotechnology, MSD, Novartis, GlaxoSmithKline, Pfizer, Chugai, and Daiichi Sankyo (institutional); S. Ohno has received honoraria from Chugai, AstraZeneca, Pfizer, Novartis, Taiho, Eisai, Kyowa Hakko Kirin; X. Huang is a stockholder in Pfizer; S. Hashigaki, Y. Muramatsu, and T. Nagasawa are employees of Pfizer; Y. Mori and Y. Umeyama are employees of, and stockholders in, Pfizer.